

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau


INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(51) International Patent Classification 6:	A1	(11) International Publication Number: WO 96/33980
C07D 239/94, A61K 31/505		(43) International Publication Date: 31 October 1996 (31.10.96)
(21) International Application Number: PCT/GB96/M0961		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 23 April 1996 (23.04.96)		
(30) Priority Data: 9508538.7 27 April 1995 (27.04.95) GB		
(71) Applicant (for all designated States except US): ZENECA LIMITED [GB/GB]; 15 Stanhope Gate, London W1Y 6LN (GB).		
(72) Inventor; and		Published
(73) Inventor/Applicant (for US only): GIBSON, Keith, Hopkins [GB/GB]; Zeneca Pharmaceuticals, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		With international search report.
(74) Agent: TAIT, Brian, Steele; ZENECA Pharmaceuticals, Intellectual Property Dept., Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).		


(54) Title: QUINAZOLINE DERIVATIVES

(57) Abstract


The invention concerns quinazoline derivatives of the formula (I) wherein n is 1, 2 or 3 and each R² is independently halogeno, trifluoromethyl or (1-4C)alkyl; R³ is (1-4C)alkoxy; and R¹ is di-[(1-4C)alkyl]amino-(2-4C)alkoxy, pyrrolidin-1-yl-(2-4C)alkoxy, piperidino-(2-4C)alkoxy, morpholino-(2-4C)alkoxy, piperazin-1-yl-(2-4C)alkoxy, 4-(1-4C)alkyl(piperazin-1-yl-(2-4C)alkoxy), imidazol-1-yl-(2-4C)alkoxy, di-[(1-4C)alkoxy-(2-4C)alkoxy]amino-(2-4C)alkoxy, thiomorpholino-(2-4C)alkoxy, 1-oxathiomorpholino-(2-4C)alkoxy or 1,1-dioxothiomorpholino-(2-4C)alkoxy, and wherein any of the above-mentioned R¹ substituents comprising a CH₂ (methylene) group which is not attached to N or O atom optionally bears on said CH₂ group a hydroxy substituent; or pharmaceutically-acceptable salts thereof; processes for their preparation, pharmaceutical compositions containing them, and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of proliferative disease such as cancer.







II



III

10

20

30

40

50

•10•

• 20 •


• 38 •

• 40 •

•50•

10

I



30

40

50

(6)

11

12


10

20

30

40

50



$\cdot 10^4$

20

30

40

50

